Race Oncology Ltd (RAC) is an Australian pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field.
The company's first important asset is a chemotherapy drug, Bisantrene, which was the subject of more than 40 phase II clinical studies. On 13 August 2019, the company announced it had secured a new patent on its cancer drug, Bisantrene, from the United States Patent and Trademarks Office.
Contact Details
Level 36, 1 Macquarie Place
,
SYDNEY
NSW
2000
02 8051 3043
info@raceoncology.com
